PL3290023T3 - Kompozycja farmaceutyczna o przedłużonym uwalnianiu zawierająca rywastygminę - Google Patents

Kompozycja farmaceutyczna o przedłużonym uwalnianiu zawierająca rywastygminę

Info

Publication number
PL3290023T3
PL3290023T3 PL16786732T PL16786732T PL3290023T3 PL 3290023 T3 PL3290023 T3 PL 3290023T3 PL 16786732 T PL16786732 T PL 16786732T PL 16786732 T PL16786732 T PL 16786732T PL 3290023 T3 PL3290023 T3 PL 3290023T3
Authority
PL
Poland
Prior art keywords
rivastigmine
pharmaceutical composition
release pharmaceutical
containing sustained
sustained
Prior art date
Application number
PL16786732T
Other languages
English (en)
Inventor
Sang Geun Park
Hye Gyeong Shin
Jeong Woo BAE
Hyun Ju Choi
Original Assignee
Navipharm Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navipharm Co., Ltd. filed Critical Navipharm Co., Ltd.
Publication of PL3290023T3 publication Critical patent/PL3290023T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16786732T 2015-04-27 2016-04-27 Kompozycja farmaceutyczna o przedłużonym uwalnianiu zawierająca rywastygminę PL3290023T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150058759A KR101990951B1 (ko) 2015-04-27 2015-04-27 리바스티그민 함유 서방출 의약조성물
PCT/KR2016/004380 WO2016175546A2 (ko) 2015-04-27 2016-04-27 리바스티그민 함유 서방출 의약조성물
EP16786732.4A EP3290023B1 (en) 2015-04-27 2016-04-27 Rivastigmine-containing sustained-release pharmaceutical composition

Publications (1)

Publication Number Publication Date
PL3290023T3 true PL3290023T3 (pl) 2021-08-30

Family

ID=57199589

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16786732T PL3290023T3 (pl) 2015-04-27 2016-04-27 Kompozycja farmaceutyczna o przedłużonym uwalnianiu zawierająca rywastygminę

Country Status (22)

Country Link
US (1) US10835497B2 (pl)
EP (1) EP3290023B1 (pl)
JP (1) JP6787928B2 (pl)
KR (1) KR101990951B1 (pl)
CN (1) CN107530290B (pl)
AU (1) AU2016255302B2 (pl)
BR (1) BR112017022478B1 (pl)
CA (1) CA2984235C (pl)
CY (1) CY1124339T1 (pl)
DK (1) DK3290023T3 (pl)
ES (1) ES2860694T3 (pl)
HR (1) HRP20210434T1 (pl)
HU (1) HUE053816T2 (pl)
LT (1) LT3290023T (pl)
MX (1) MX380909B (pl)
PL (1) PL3290023T3 (pl)
PT (1) PT3290023T (pl)
RS (1) RS61548B1 (pl)
RU (1) RU2727721C2 (pl)
SI (1) SI3290023T1 (pl)
SM (1) SMT202100208T1 (pl)
WO (1) WO2016175546A2 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102209420B1 (ko) * 2019-03-08 2021-01-29 에이치엘비제약 주식회사 리바스티그민의 일정한(0-차) 방출형 경구용 서방성 정제 조성물
CN112546037A (zh) * 2020-12-08 2021-03-26 苏州大学 卡巴拉汀在制备抗辐射药中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1406126A (zh) * 1998-10-01 2003-03-26 诺瓦提斯公司 新型缓释口服制剂
JP2003507416A (ja) * 1999-08-26 2003-02-25 エラン コーポレイション ピーエルスィー 医薬製剤
CA2380333A1 (en) 1999-08-26 2001-03-01 Christian Andina Pharmaceutical formulations
GB9923045D0 (en) 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US20050163847A1 (en) * 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
RU2390354C2 (ru) 2004-12-27 2010-05-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Препарат матричного типа с замедленным высвобождением, содержащий основное лекарственное средство или его соль, и способ его получения
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
JP2008535837A (ja) * 2005-04-06 2008-09-04 マリンクロッド・インコーポレイテッド マトリックスをベースとするパルス放出製剤
EP1958111A4 (en) * 2005-11-29 2009-07-08 Childrens Hosp Medical Center OPTIMIZATION AND INDIVIDUALIZATION OF THE SELECTION AND DOSAGE OF MEDICAMENTS
AU2006343596A1 (en) * 2006-05-12 2007-11-22 Shire Llc Controlled dose drug delivery system
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US8632805B2 (en) 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
JP5827952B2 (ja) 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドYungjin Pharm. Co. Ltd. 速効性と持続性を同時に有する薬剤学的組成物
JP2013523757A (ja) * 2010-03-31 2013-06-17 スパーナス ファーマシューティカルズ インコーポレイテッド マジンドールの製剤
MX2015011896A (es) * 2013-03-15 2016-07-19 Korea United Pharm Inc Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia.

Also Published As

Publication number Publication date
EP3290023A4 (en) 2018-12-19
WO2016175546A3 (ko) 2016-12-22
HUE053816T2 (hu) 2021-07-28
RU2727721C2 (ru) 2020-07-23
RU2017136567A (ru) 2019-05-27
MX2017013481A (es) 2018-05-17
KR101990951B1 (ko) 2019-06-20
CA2984235C (en) 2023-02-21
WO2016175546A2 (ko) 2016-11-03
DK3290023T3 (da) 2021-04-12
LT3290023T (lt) 2021-03-25
ES2860694T3 (es) 2021-10-05
SMT202100208T1 (it) 2021-05-07
PT3290023T (pt) 2021-03-24
HRP20210434T1 (hr) 2021-04-30
MX380909B (es) 2025-03-12
CY1124339T1 (el) 2022-07-22
BR112017022478B1 (pt) 2023-11-21
RU2017136567A3 (pl) 2019-09-19
CN107530290A (zh) 2018-01-02
EP3290023B1 (en) 2021-02-17
CA2984235A1 (en) 2016-11-03
RS61548B1 (sr) 2021-04-29
KR20160127405A (ko) 2016-11-04
BR112017022478A2 (pt) 2018-07-10
AU2016255302A1 (en) 2017-12-07
JP6787928B2 (ja) 2020-11-18
SI3290023T1 (sl) 2021-08-31
CN107530290B (zh) 2021-04-27
US10835497B2 (en) 2020-11-17
EP3290023A2 (en) 2018-03-07
US20180125785A1 (en) 2018-05-10
JP2018514530A (ja) 2018-06-07
AU2016255302B2 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
IL265260B (en) pharmaceutical preparations
IL265360A (en) Pharmaceutical composition
IL262654A (en) Pharmacy preparation
IL258213A (en) Pharmaceutical compounds
GB201504675D0 (en) Pharmaceutical compounds
GB201506658D0 (en) Pharmaceutical compounds
GB201519352D0 (en) Pharmaceutical compounds
GB201506660D0 (en) Pharmaceutical compounds
IL258246A (en) Pharmaceutical compounds
IL265349A (en) Pharmaceutical composition
GB201506933D0 (en) Pharmaceutical compounds
GB201502567D0 (en) Pharmaceutical compounds
GB201521462D0 (en) Pharmaceutical composition
IL263040A (en) Pharmaceutical composition comprising eteplirsen
EP3272362A4 (en) Sustained-release pharmaceutical composition
IL255510A (en) Pharmaceutical compositions
PL3454838T3 (pl) Kompozycja farmaceutyczna
GB201615917D0 (en) Pharmaceutical composition
GB201515310D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
IL265436B (en) Pharmacy preparation
PT3290023T (pt) Composição farmacêutica de libertação sustentada contendo rivastigmina
GB201615910D0 (en) Pharmaceutical composition
GB201611920D0 (en) Pharmaceutical compositions